Brown, Elizabeth J
Farnie, Gillian
Bullock, Alex N
2019-05-06
<p>A description of how an limiting dilution assay was developed to test the stem-cell-like compartment within the HSJD-DIPG-007 patient derived cell line.</p>
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
https://doi.org/10.5281/zenodo.2669443
oai:zenodo.org:2669443
eng
Zenodo
https://zenodo.org/communities/sgc-opennotebook
https://zenodo.org/communities/openlabnotebooks
https://doi.org/10.5281/zenodo.2669442
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
limiting dilution assay
stemness
diffuse intrinsic pontine glioma
dipg
tumour initiating cells
patient derived cells
Determining the fraction of cells with stem-like properties in the HSJD DIPG 007 cell line by limiting dilution assay
info:eu-repo/semantics/article